Navigation Links
Oligomerix Awarded Phase IIB Grant From the NIH to Discover Drugs that Inhibit Alzheimer's Disease Progression

NEW YORK, Sept. 10, 2013 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the receipt of a two-year Small Business Innovation Research (SBIR) Phase IIB grant for $1.7M from the National Institutes of Health (NIH), National Institute on Aging (NIA).

The proceeds from this grant will be used to extend the Company's research for the development of small molecule drugs aimed specifically at inhibiting tau aggregation at the earliest steps of tau self-association into toxic oligomers in neurons. This approach may be effective in reducing extracellular tau oligomers, including dimers and trimers that have recently been reported to be involved in the spread of tau pathology and to impair memory formation in animal models of AD. A drug that reduces tau oligomer levels may lead to both an improvement in memory and a slowing or complete suspension of disease progression in AD patients and would therefore be a disease-modifying therapeutic.

James Moe, Ph.D., MBA, President and CEO of Oligomerix, stated, "We're pleased to be receiving this support, as it validates our approach and will allow us to advance our programs geared toward inhibiting tau oligomer formation that we believe plays a crucial role in AD progression. This program will allow us to evaluate our lead candidates in animal models of AD and related tauopathies with the goal of selecting candidates for IND enabling studies, a prelude to initial clinical evaluation." 

Oligomerix, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The Company was founded in 2006 and is headquartered at Audubon Biomedical Science and Technology Park at Columbia University Medical Center and is carrying out its in vivo studies at New York Medical College.  The Company is seeking strategic partners to help accelerate these exciting programs.  For more information, visit

Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding contract research and services.

Oligomerix, Inc.
Jack Pasini
Chief Commercial Officer

Tiberend Strategic Advisors, Inc.
Andrew Mielach

SOURCE Oligomerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
2. Carolina Piedmont Capital Awarded VOSB Certification
3. B. Braun Awarded Premier Healthcare Alliance Contract for Dual-Source IV
4. Novan Awarded $7.8 Million Contract by BARDA to Develop a Medical Countermeasure for Thermal Burns
5. Fountain Valley Regional Medical Center Becomes Orange Countys First Hospital Awarded Advanced Certification In Inpatient Diabetes Care
6. aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
7. Arisaph Pharmaceuticals Awarded Phase I STTR Grant To Develop Small Molecule Immune Modulators
8. All Time Medical awarded a Google Trusted Store badge.
9. Dynamic Healthcare Services Awarded Two Oxygen Equipment Competitive Bidding Contracts
10. Instrumentation Laboratory Awarded Premier Healthcare Alliance Contract For Hemostasis Product Line
11. Great Lakes NeuroTechnologies Awarded Patent For Technology To Treat Parkinsons Disease With Brain Stimulation During Sleep
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 3D bioprinting market ... according to a new report by Grand View Research Inc. ... (CKD) which demands kidney transplantation is expected to boost the ... substitute for organ transplantation. --> 3D bioprinting market ... according to a new report by Grand View Research Inc. ...
(Date:11/26/2015)... 26, 2015 ... ser potential att använda SyMRI för att ... för patienter med multipel skleros (MS) eller ... SyntheticMR AB för att kunna använda SyMRI ... Med SyMRI kan man generera flera konstrastbilder ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... American Dental Association meeting in Washington D.C. revolved around the fact that proper dental ... health. The talk stressed the link between periodontal disease (more commonly referred to as ...
(Date:11/27/2015)... ... ... According to an article published November 15th by ABC News, while ... light of the recent terrorist attacks in Paris, other cities are taking extra precautions ... reaching U.S. soil. Especially around special events that may be high-profile in nature, the ...
(Date:11/27/2015)... ... ... A team of Swiss doctors has released a report on mesothelioma relapse ... the findings on the website. Click here to read the details now. ... who were treated with chemotherapy followed by EPP surgery. Among the 106 patients who ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When ... said an inventor from Hillside, N.J. "Many people catch diseases simply from sitting ... individuals will always be protected from germs." , He developed the patent-pending QUDRATECS ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the November 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, ... of 750,000. The digital component is distributed nationally, through a vast social media ...
Breaking Medicine News(10 mins):